PALO ALTO, Calif.--(BUSINESS WIRE)--Inscopix Inc., a leading neurotechnology company in California that empowers breakthroughs in brain science, announced today that Martin Verhoef has joined the company as Chief Commercial Officer. As a key member of Inscopix’s executive leadership team, Mr. Verhoef will lead all commercial operations, spanning strategy, sales, marketing, business development and customer success.
Mr. Verhoef brings over thirty years of leadership experience in the life science tools and technology industry. He joins Inscopix from the Danaher corporation, where he served as VP of Innovation, Danaher Life Science Instruments Group. Prior to that, he led Strategy, Marketing, and R&D at Molecular Devices for six years. Mr. Verhoef has also worked as the CEO of Primera Dx and Executive VP of Ciphergen Biosystems, and in various roles at Hewlett Packard / Agilent.
Dr. Kunal Ghosh, CEO & Founder of Inscopix said, “I am very pleased to welcome Martin Verhoef to the Inscopix team. Martin has a stellar track record in commercializing new platforms for life science discovery and clinical applications, and I have no doubt that his wealth of experience will help propel Inscopix to the next level as we seek expansion in the neuroscience research market and make an impact on human brain health.”
"I am honored and thrilled to join Inscopix, a company that is pushing the frontiers of neuroscience and preclinical therapeutic development through cutting-edge innovations,” said Mr. Verhoef. “I look forward to helping scale Inscopix’s growth and to translate the world class neuroscience already catalyzed by the company’s brain-mapping platform into cutting-edge neurotherapies for brain disorders such as Parkinson’s, Autism, depression, and Alzheimer’s.”
Mr. Verhoef received his double bachelor’s degree in Clinical Chemistry (1980) and Analytical Chemistry (1985), both from the Van 't Hoff Institute, Rotterdam, The Netherlands.
About Inscopix, Inc.
Inscopix empowers the development of next-generation therapeutics for difficult-to-treat brain disorders by enabling innovative research and predictive preclinical therapeutic development. Driven by a North Star of overcoming historic challenges in the field, Inscopix provides validated solutions for real-time mapping of neural activity in brain circuits. These objective, quantitative and in-brain assays are catalyzing unprecedented insights into disease mechanisms and have been shown to be more accurate at predicting clinical efficacy than animal behavior when testing a therapeutic candidate's capacity to bring the brain back to a normal state. Inscopix's partner and customer discoveries help decode the brain, inform deeper understanding of mechanisms of action and enable the screening of drugs based on efficacy. For more information, please visit http://www.inscopix.com.